2022

1. MASH drug candidate (J2H-1702) entered phase 2 clinical trial
2. New drug candidate for multiple sclerosis (J2H-1801) entered GLP Toxicity studies/NSCLC PROTAC drug candidate (J2H-2002) entered GLP Toxicity studies
3. Pharmaceutical business division (Ansan) facility received kGMP certification

2021

1. Clinical research team established
2. Development of novel drug R&D platform technology PROTACTICS^®
3. Pharmaceutical business division established (Ansan)

2020

1. MASH drug candidate (J2H-1702) entered phase 1 clinical trial
2. Received Inno-Biz technology innovation small and medium enterprise certification/Designated as the excellent corporation R&D center (Ministry of Science and ICT)
3. Established Fine chemicals division Asan facility

2019

1. Selected as the Preliminary unicorn company (Ministry of SMEs and Startups)
2. Development of R&D platform technology, OPTIFLEX^®

2018

1. J2H Tenofovir disoproxil approved by Korean Ministry of Food and Drug Safety

2017

1. HQ relocated/Opened R&D center (Suwon venture valley II)
2. Won patent lawsuit for the blockbuster generic against 11 pharmaceutical companies

2015

1. Certified as a venture company (Korean venture capital association) & certified as Company affiliated research institute (Korea Industrial Technology Association)

2014

1. Founding of J2H Biotech